References
- Bravo EL. Evolving concepts in the pathophysio-logy, diagnosis and treatment of pheochromocy-tom. Endocrine Rev 1994; 15: 356–69
- Krane NK. clinically unsuspected pheochromocy-tom: experience at Henry Ford Hospital and a review of the literature. Arch Intern Med 1986; 146: 54–7
- Nativ O, Grant CS, Sheps SG, O'Fallon JR, Farrow GM, van Heerden JA, et al. The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma. Cancer 1992; 69: 2683–7
- Fischer-Colbrie R, Lassmann H, Hagn C, Winkler H. Immunological studies on the distri bution of chromogranin A and B in endocrine and nervous tissue. Neuroscience 1985; 16: 547–55
- O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal sub jects and patients with pheochromocytoma. N Engl J Med 1984; 311: 764–70
- Cryer PE, Wortmann J, Sha SD, Nowak RM, Deftos LJ. Plasma chromogranin A as a marker for sympathochromaffin activity in humans. Am J Physiol 1991; 260: E243–6
- Stridsberg M, Hellman U, Wilander E, Lund-Qvist G, Hellsing K, Ouberg K. Fragments of chro mogranin A are present in the urine of patients with carcinoid tumors: development of a specific radio immunoassay for chromogranin A and its frag ments. J Endocrinol 1993; 139: 329–37
- Stridsberg M, Öberg K, Li Q, Engström U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144: 49–59
- Hsiao RJ, Neumann HPH, Parmer R, Barbosa JA, O'Connor DT. Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kin etics indicating twocompartment distribution. Am J Med 1990; 88: 607–13
- Helle KB, Marley PD, Angeletti RH, Aunis D, Galindo E, Small DH, Livett BG. Chromo granin A: secretion of processed products from stimulated retrogradely perfused bovine adrenal gland. J Neuroendocrinol 1993; 5: 405–12
- Angeletti RH, Aardal S, Serck-Hanssen G, Gee P, Helle KB. Vasoinhibitory activity of synthetic pep-tides from the amino terminus of the adrenomedui-lary chromogranin A. Acta Physiol Scand 1994; 152: 11–19
- Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence from extracellular calcium in iso lated segments of human blood vessels. Regul Pept 1992; 41: 9–18
- Aardal S, Helle KB, Elsayed S, Reed RK, Serck-Hanssen G. Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in human blood vessel segments. J Neuroendocrinol 1993; 5: 405–12
- Miura Y, Yoshinaga K. Doxazosin. A newly devel oped, selective α1--inhibitor in the management of patients with pheochromocytoma. Am Heart J 1988; 116: 1785–9
- Taupenot L, Remacle JE, Helle KB, Aunis D, Bader M-F. Recombinant human chromogranin A: expression, purification and characterization of the N-terminal derived peptides. Regul Pept 1995; 56: 71–88
- Galindo E, Rill A, Bader M-F, Aunis D. Chromostatin, a 20-amino acid peptide derived from chromogranin A, inhibits chromaffin cell secretion. Roc Natl Acad Sci USA 1991; 88: 426–30
- Causon RC, Carruthers ME, Rodnight R. Assay of plasma catecholamines by liquid chromato-graphy with electrochemical detection. Anafyt Biochem 1981; 116: 223–6
- Eriksson BM, Person BA. Determination of cate cholamines in the rat heart tissue and plasma samples by liquid chromatography with electro chemical detection. J Chromatogr 1982; 228: 143–54
- Flöysand R, Serck-Hanssen G. Determination of tissue contents of catecholamines in Atlantic salmon (Salmo salar):a comparison of HPLC-EC and the trihydroxyindol fluorimetric method. Comp Biochem Physiol 1991; 99C: 457
- Canale MP, Bravo E. Diagnostic specificity of serum chromogranin A for pheochromocytoma patients with renal dysfunction. J Clin Endocrinol Metab 1994; 78: 1139–44
- Syversen U, Waldum HL, O'Connor DT. Rapid, high-yield isolation of human chromogranin A from chrornaffin granules of pheochromocytomas. Neuropeptides 1992; 22: 235–40
- Helle KB, Angeletti RH, Chromogranin A. a multi purpose prohormone?. Acta Physiol Scand 1994; 152: 1–16
- Weiler R, Steiner H-J, Fischer-Colbrie R, Schmid KW, Winkler H. Undegraded chromogranin A is present in serum and enters the endocytotic lysoso-mal pathway in kidney. Histochemistry 1991; 96: 395–9